Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The initiation criterion is utilized to predict the critical detonation condition of explosives and plays a dominant role in the fields of survivability, vulnerability, and safety. In order to predict the threshold criterion of explosives initiated by fragment impact in three-dimensional scenarios, the detonation threshold velocities of Comp B (61% Hexahydro-1,3,5-trinitro-1,3,5-triazine, 39% 2,4,6-trinitrotoluene) explosive charges with different radii under the fragment impact at different polar angles and azimuth angles were obtained by numerical calculations, and further, a three-dimensional initiation criterion was established. The results show that when the impact polar angle of the fragment is fixed, the critical velocity under the same azimuth angle scenario increases as the radius of the charge decreases. When the impact azimuth angle of the fragment is fixed, the critical velocity under the same polar angle scenario is almost unaffected by the charge radius. The maximum error between the three-dimensional initiation criterion and the simulation is 3.09%, indicating the high accuracy of the established initiation criterion.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317034PMC
http://dx.doi.org/10.1038/s41598-025-08750-4DOI Listing

Publication Analysis

Top Keywords

initiation criterion
16
critical velocity
12
fragment impact
12
explosive charges
8
initiated fragment
8
charge radius
8
impact polar
8
three-dimensional initiation
8
polar angle
8
angle fragment
8

Similar Publications

Vedolizumab Achieves Pan-Enteric Mucosal Healing in Crohn's Disease: A Prospective Observational Study.

United European Gastroenterol J

September 2025

Sheba Medical Center Tel Hashomer, Faculty of Medical and Health Sciences, Gastroenterology Institute, Tel-Aviv University, Tel Aviv, Israel.

Background: Mucosal healing (MH) is a key treatment goal in Crohn's disease (CD). However, evidence on pan-enteric MH (PE-MH) in CD patients treated with vedolizumab remains limited. We aimed to assess vedolizumab efficacy in achieving PE-MH using PillCam Crohn's capsule.

View Article and Find Full Text PDF

Objective: To identify the major barriers to and facilitators of implementing the Lebanese Health Economic Evaluation Guideline (LEEG) according to Lebanese stakeholders, supported by their insights.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬.

Methods: We conducted a survey asking 16 key stakeholders to rate LEEG's importance, its necessity for Lebanon, and its applicability in decision-making, and Likert scale questions to rate barriers and facilitators.

View Article and Find Full Text PDF

Background: Given well-established efficacy of contingency management (CM), demand grows for effective implementation support. Coaching-to-criterion is a strategy for assuring workforce capability to deliver CM programming with fidelity. To what extent this preparative strategy is comparably useful for addiction professionals and peer specialists is unknown.

View Article and Find Full Text PDF

A common eligibility criterion in respiratory clinical trials is a per cent-predicted forced expiratory volume in 1 second (ppFEV) between 40% and 90%, using the ethnicity-dependent Global Lung Function Initiative (GLI)-2012 spirometry reference equations. International societies now endorse the newer 'race-neutral' GLI-Global equations. We quantify the impact on trial eligibility of switching from GLI-2012 to GLI-Global for the UK Cystic Fibrosis Registry (n=8182).

View Article and Find Full Text PDF

The goals of treatment for people with advanced cancer are to prolong survival and improve symptoms and health-related quality of life (HRQOL). Although many phase 3 randomised clinical trials seek to evaluate HRQOL during treatment, informing individual patients about expected HRQOL outcomes is challenging, as the common method of analysis and reporting compares averages for randomised groups, and clinicians find these data difficult to apply in clinical practice. Symptomatic patients with advanced cancer would like to know the probability that a proposed treatment might improve their survival or their dominant symptoms, and the probability of having treatment-related side-effects.

View Article and Find Full Text PDF